12:00 AM
Apr 07, 2003
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MG98: Phase I

In a Canadian Phase I trial, MG98 was well tolerated and caused objective tumor response or disease stabilization. MG98 is in U.S. and EU Phase...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >